(-0.01%) 5 478.00 points
(-0.04%) 38 803 points
(0.04%) 19 929 points
(0.27%) $80.55
(1.15%) $2.82
(0.15%) $2 332.40
(-0.26%) $29.32
(-0.10%) $969.90
(0.02%) $0.932
(-0.15%) $10.64
(0.08%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications...
Stats | |
---|---|
Šios dienos apimtis | 43 354 |
Vidutinė apimtis | 9 843 |
Rinkos kapitalizacija | 0.00 |
EPS | $-0.0238 ( Q2 | 2020-09-11 ) |
Last Dividend | $160.67 ( 2017-09-12 ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.199 (10.21%) |
Tūris Koreliacija
Forward Pharma A/S Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Forward Pharma A/S Koreliacija - Valiuta/Žaliavos
Forward Pharma A/S Finansinės ataskaitos
Annual | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.280 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.280 |
FY | 2020 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.980 |
FY | 2019 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.560 |
Financial Reports:
No articles found.
Forward Pharma A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $160.67 | 2017-09-12 |
Last Dividend | $160.67 | 2017-09-12 |
Next Dividend | $0 | N/A |
Payout Date | 2017-09-11 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $160.67 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.66 | -- |
Div. Sustainability Score | 3.56 | |
Div.Growth Potential Score | 0.779 | |
Div. Directional Score | 2.17 | -- |
Year | Amount | Yield |
---|---|---|
2017 | $160.67 | 1 046.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
12 Sep 2017 | $160.67 | 25 Aug 2017 | 07 Sep 2017 | 11 Sep 2017 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.479 | 1.500 | -9.57 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00126 | 1.200 | 9.96 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00120 | 1.500 | -1.098 | -1.647 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 117.44 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 116.63 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 116.40 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 1.955 | 1.000 | -0.387 | -0.387 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.338 | 2.00 | -0.113 | -0.225 | [0 - 30] |
freeCashFlowPerShareTTM | -0.338 | 2.00 | -0.169 | -0.338 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 1.000 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 20.61 | 1.000 | 10.00 | 10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | -0.00263 | 0.800 | -3.35 | -2.68 | [0.5 - 2] |
Total Score | 3.56 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 151.31 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00120 | 2.50 | -0.706 | -1.647 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.338 | 2.00 | -0.113 | -0.338 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.338 | 2.00 | -0.113 | -0.225 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -3.48 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 12.55 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 0.779 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Forward Pharma A/S
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.